Read by QxMD icon Read

Diabetes Research and Clinical Practice

Aye C Paing, Alison F Kirk, Andrew Collier, Thomas Kubiak, Sebastien F M Chastin
AIMS: To assess continuous glucose monitoring (CGM) derived intra-day glucose profiles using global guideline for type 2 diabetes recommended by the International Diabetes Federation (IDF). METHODS: The Cochrane Library, MEDLINE, PubMed, CINAHL and Science Direct were searched to identify observational studies reporting intra-day glucose profiles using CGM in people with type 2 diabetes on any anti-diabetes agents. Overall and subgroup analyses were conducted to summarise mean differences between reported glucose profiles (fasting glucose, pre-meal glucose, postprandial glucose and post-meal glucose spike/excursion) and the IDF targets...
November 3, 2018: Diabetes Research and Clinical Practice
Andy Shaw, David Houghton, Kate Hallsworth, Djordje G Jakovljevic, Michael Trenell, Sophie Cassidy
Cardiorespiratory fitness (CRF) is impaired in those with metabolic diseases and strongly predicts mortality. We found that adiposity, not glycaemic control or disease type, is the strongest predictor of low CRF in those with metabolic diseases. We discuss how adiposity and metabolic health may relate to outcomes in obesity.
November 1, 2018: Diabetes Research and Clinical Practice
Tomomichi Koshi, Hiroyuki Sagesaka, Yuka Sato, Kazuko Hirabayashi, Hideo Koike, Keishi Yamauchi, Rimei Nishimura, Mitsuhiko Noda, Koh Yamashita, Toru Aizawa
AIMS: To compare impact of elevated HbA1c and fasting plasma glucose (FPG) on incident chronic kidney disease (CKD) in a non-diabetic cohort. METHODS: Data from diabetes- and CKD-free 25,109 health examinees were retrospectively analysed with a mean observation period of 5.3 years. Prediabetes was diagnosed by the ADA and WHO criteria, and CKD by estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 and/or dipstick proteinuria. Cox proportional hazards model was applied with sex, age, insulin sensitivity, systolic blood pressure, eGFR and serum alanine aminotransferase level as covariates...
November 1, 2018: Diabetes Research and Clinical Practice
Takahiro Yajima, Keigo Yasuda
No abstract text is available yet for this article.
November 1, 2018: Diabetes Research and Clinical Practice
Yuji Komorita, Masanori Iwase, Hiroki Fujii, Hitoshi Ide, Toshiaki Ohkuma, Tamaki Jodai-Kitamura, Akiko Sumi, Masahito Yoshinari, Udai Nakamura, Takanari Kitazono
AIMS: Sarcopenia is involved in the pathogenesis of increased fracture risk associated with diabetes. The serum creatinine to cystatin C (Cr/CysC) ratio has been reported as a surrogate marker for muscle mass. We aimed to prospectively investigate the relationship between the Cr/CysC ratio and fracture risk. METHODS: We followed 1911 postmenopausal women and 2689 men with type 2 diabetes (mean age, 66 years) for a median of 5.3 years, and divided into Cr/CysC ratio quartiles by sex...
November 1, 2018: Diabetes Research and Clinical Practice
Larry A Weinrauch, Karim H Anis, John A D'Elia
Solid organ transplant candidates undergo very strict screening for cardiovascular risk. Such screening has permitted significant decreases in cardiovascular morbidity and mortality over the ensuing decades of follow up. Long term follow-up has enabled us to identify an increasing incidence of pulmonary and urinary tract infections with or without sepsis as competing factors of morbidity and mortality. Indeed, all-cause mortality may now be dominated by infection-related endpoints. No population of transplant recipients is more naturally susceptible to infection as a diabetic subset, now submitted to immunosuppression...
October 31, 2018: Diabetes Research and Clinical Practice
Marina V Shestakova, John P H Wilding, Wim Wilpshaar, Reiner Tretter, Valeria L Orlova, Andrey F Verbovoy
AIM: To assess the efficacy and safety of ipragliflozin as add-on therapy to metformin in Russian patients with type 2 diabetes mellitus. METHODS: In this double-blind study conducted in 14 centers in Russia, 165 patients were randomized 2:1 to ipragliflozin (50 mg/day) or placebo for 24 weeks while continuing metformin. Patients who had HbA1c ≥7.0% (53 mmol/mol) at Week 12 received open-label ipragliflozin (50 mg/day) in addition to the blinded drug from Week 12-24...
October 31, 2018: Diabetes Research and Clinical Practice
Stefan Kopf, Jan B Groener, Zoltan Kender, Thomas Fleming, Sandra Bischoff, Johann Jende, Carsten Schumann, Stefan Ries, Martin Bendszus, Sigrid Schuh-Hofer, Rolf-Detlef Treede, Peter P Nawroth
AIMS: The aim of the study was to assess whether quantitative-sensory-testing could be used to evaluate prevalence and predictors of diabetic neuropathy (DPNP) in patients with pre-diabetes and type 2 diabetes. METHODS: Twenty-eight pre-diabetics and 108 patients with type 2 diabetes were evaluated using neuropathy-deficit-score (NDS), neuropathy-symptom-score (NSS), nerve-conduction-studies (NCS), short-QST-protocol to examine small fibers and the comprehensive QST-battery (long-QST) according to the German Research Network on Neuropathic Pain protocol...
October 31, 2018: Diabetes Research and Clinical Practice
Min Shang, Zhaoyang Wen
AIMS: Newborns of women with gestational diabetes mellitus(GDM) are susceptible to be macrosomic, even if the blood glucose levels are in normal ranges. The underlying mechanisms are largely unknown. We tested the hypothesis that placental insulin like growth factor(IGF)-I and mammalian target of rapamycin (mTOR) signaling is activated and amino acid transporter expression is increased in women with GDM who give birth to macrosomic babies. METHODS: 50 Chinese pregnant women with GDM whose blood glucose levels were controlled within normal range were recruited and their placental tissues were collected...
October 31, 2018: Diabetes Research and Clinical Practice
Md Azharuddin, Mohammad Adil, Pinaki Ghosh, Manju Sharma
AIM: To perform a systematic literature review and network meta-analysis (NMA) of randomized controlled trials (RCTs) to estimate effect of SGLT2 inhibitors on fracture risk in patients with T2DM. METHODS: A systematic search was performed on PubMed/Medline and from inception to May 2018 to identify RCTs reporting fracture events with the use of SGLT2 inhibitors compared to control group in patients with T2DM. NMA within a Bayesian framework was performed to calculate the odds ratio (OR) and 95% credible intervals (CrI) using random effect model...
October 31, 2018: Diabetes Research and Clinical Practice
Sascha Reiff, Stephen Fava
BACKGROUND: Type 2 diabetes is associated with increased mortality. There is some data that sulphonylurea therapy may contribute to this. AIMS: To compare all-cause 3-year mortality of patients on sulphonylurea monotherapy with of patients on metformin monotherapy after adjusting for potential confounders. METHODS: We searched the Maltese national electronic database for diabetes treatment in April 2014. This is an electronic database of all treatment that patients are prescribed through the local National Health Service...
October 30, 2018: Diabetes Research and Clinical Practice
Joshua Palaya, Sue Pearson, Toni Nash
AIM: To explore the perception of social support in individuals living with a diabetic foot in order to influence future service delivery in management of similar individuals. METHOD: A purposive sample of eight participants with a diabetic foot were recruited from a public podiatry service in Tasmania, Australia. A hermeneutic phenomenology qualitative approach was used with individual semi-structured interviews conducted using an interview guide designed to gain insight into five pre-determined measures of social support...
October 30, 2018: Diabetes Research and Clinical Practice
Konosuke Nagae, Hiroshi Uchi, Saori Morino-Koga, Yuka Tanaka, Mari Oda, Masutaka Furue
AIMS: Diabetes induces various skin troubles including foot ulcer. This type of skin ulcer is refractory but the pathogenesis is not so certain. Recent study show that glucagon-like peptide-1 (GLP-1) analogues reduce foot complications with diabetes (Pérez et al., 2015), however, the role of GLP-1/GLP-1R axis is not fully understood, and clear evidence of GLP-1 to facilitate wound closure is still lacking. In this study, we investigated whether a potent GLP-1R agonist liraglutide affects wound healing process...
October 25, 2018: Diabetes Research and Clinical Practice
S Lanzinger, S M Schmid, R Welp, A Zimmermann, P Fasching, S Wagner, R W Holl
OBJECTIVES: Failure to intensify treatment of patients with type 2 diabetes (T2D) in a timely manner is a common challenge. If newer oral anti-diabetic drugs (NOADs) such as dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium/glucose cotransporter 2 inhibitors (SGLT-2i) do not achieve metabolic control, injectable therapy like insulin or glucagon-like Peptide 1 (GLP-1) receptor agonists are required. We investigated the time in poor glycaemic control (PC, HbA1c > 7%, >7.5%, >8%) in adults with T2D treated with DPP-4i/SGLT-2i until treatment intensification with insulin/GLP-1 or until the most recent documented visit...
October 24, 2018: Diabetes Research and Clinical Practice
Natalia G Vallianou, Theodora Stratigou, Stylianos Tsagarakis
Alterations in the diversity or structure of gut microbiota known as dysbiosis, may affect metabolic activities, resulting in metabolic disorders, such as obesity and diabetes. The development of more sophisticated methods, such as metagenomics sequencing, PCR-denaturing gradient gel electrophoresis, microarrays and fluorescence in situ hybridization, has expanded our knowledge on gut microbiome. Dysbiosis has been related to increased plasma concentrations of gut microbiota-derived lipopolysaccharide (LPS), which triggers the production of a variety of cytokines and the recruitment of inflammatory cells...
October 18, 2018: Diabetes Research and Clinical Practice
Masashi Tanaka, Takanori Honda, Hajime Yamakage, Jun Hata, Daigo Yoshida, Yoichiro Hirakawa, Mao Shibata, Takayuki Inoue, Toru Kusakabe, Noriko Satoh-Asahara, Toshiharu Ninomiya
AIMS: No cohort study has examined the pathological significance of triggering receptor expressed on myeloid cell 2 (TREM2), a cell surface receptor expressed on myeloid lineage cells, and its soluble form, sTREM2, in insulin resistance in a general population. METHODS: A total of 2,742 community-dwelling Japanese individuals aged ≥40 years were divided into 4 groups according to the serum sTREM2 concentration quartiles. We examined the cross-sectional association of sTREM2 levels with anthropometric parameters and the homeostasis model assessment of insulin resistance (HOMA-IR)...
October 16, 2018: Diabetes Research and Clinical Practice
Lise Bankir, Nadine Bouby, Robert C Speth, Gilberto Velho, Gilles Crambert
Glucagon secretion is stimulated by a low plasma glucose concentration. By activating glycogenolysis and gluconeogenesis in the liver, glucagon contributes to maintain a normal glycemia. Glucagon secretion is also stimulated by the intake of proteins, and glucagon contributes to amino acid metabolism and nitrogen excretion. Amino acids are used for gluconeogenesis and ureagenesis, two metabolic pathways that are closely associated. Intriguingly, cyclic AMP, the second messenger of glucagon action in the liver, is released into the bloodstream becoming an extracellular messenger...
October 16, 2018: Diabetes Research and Clinical Practice
C Santucci, M Franchi, L Staszewsky, C La Vecchia, R Latini, L Merlino, G Corrao, C Bosetti
BACKGROUND AND AIMS: There are concerns that incretin-based antidiabetic drugs - including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists - increase the risk of hospitalization for heart failure (HF). To further analyse this issue, we conducted a nested case-control study within a cohort of antidiabetic users in a real world setting. METHODS AND RESULTS: Within a cohort of 133,639 subjects with a first prescription of an antidiabetic drug (new-users) between 2010 and 2016 in Lombardy, Italy, and were followed-up to 2016, we identified 4057 subjects with a first hospitalization for HF and 80,450 controls matched on sex, age, and date of cohort-entry...
October 14, 2018: Diabetes Research and Clinical Practice
Klemen Dovc, Kevin Cargnelutti, Anze Sturm, Julij Selb, Natasa Bratina, Tadej Battelino
AIMS: The objective of this nationwide population-based cohort study was to evaluate the correlation between continuous glucose monitoring (CGM) use and glucose variability in pre-schoolers with type 1 diabetes. METHODS: We analysed data from the Slovenian National Registry. The primary endpoint was the difference in glucose variability between periods, during which participants were using CGM and periods, during which CGM was not used, over 5 years. RESULTS: A total of 40 children <8 years old were followed for an estimated observational period of 116 patient/years...
October 14, 2018: Diabetes Research and Clinical Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"